vs
Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
EyePoint, Inc. is the larger business by last-quarter revenue ($5.3M vs $2.9M, roughly 1.9× Peraso Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -1114.3%, a 1071.0% gap on every dollar of revenue. On growth, Peraso Inc. posted the faster year-over-year revenue change (-22.0% vs -43.7%). Over the past eight quarters, Peraso Inc.'s revenue compounded faster (1.0% CAGR vs -40.8%).
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
EYPT vs PRSO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $2.9M |
| Net Profit | $-59.4M | $-1.2M |
| Gross Margin | — | 52.2% |
| Operating Margin | -1166.8% | -44.6% |
| Net Margin | -1114.3% | -43.3% |
| Revenue YoY | -43.7% | -22.0% |
| Net Profit YoY | -92.8% | 20.3% |
| EPS (diluted) | $-0.85 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | $5.3M | $2.2M | ||
| Q1 25 | $24.5M | $3.9M | ||
| Q4 24 | $11.6M | $3.7M | ||
| Q3 24 | $10.5M | $3.8M | ||
| Q2 24 | $9.5M | $4.2M | ||
| Q1 24 | $11.7M | $2.8M |
| Q4 25 | — | $-1.2M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | $-59.4M | $-1.8M | ||
| Q1 25 | $-45.2M | $-471.0K | ||
| Q4 24 | $-41.4M | $-1.6M | ||
| Q3 24 | $-29.4M | $-2.7M | ||
| Q2 24 | $-30.8M | $-4.4M | ||
| Q1 24 | $-29.3M | $-2.0M |
| Q4 25 | — | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | 93.0% | 47.0% | ||
| Q2 24 | 85.2% | 55.5% | ||
| Q1 24 | 93.5% | 46.4% |
| Q4 25 | — | -44.6% | ||
| Q3 25 | — | -36.8% | ||
| Q2 25 | -1166.8% | -80.0% | ||
| Q1 25 | -199.7% | -13.3% | ||
| Q4 24 | -390.4% | -44.3% | ||
| Q3 24 | -311.2% | -70.3% | ||
| Q2 24 | -364.5% | -105.6% | ||
| Q1 24 | -285.2% | -128.9% |
| Q4 25 | — | -43.3% | ||
| Q3 25 | — | -37.4% | ||
| Q2 25 | -1114.3% | -82.4% | ||
| Q1 25 | -184.8% | -12.2% | ||
| Q4 24 | -357.3% | -42.4% | ||
| Q3 24 | -279.0% | -70.6% | ||
| Q2 24 | -325.3% | -104.4% | ||
| Q1 24 | -250.6% | -72.1% |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | — | $-0.17 | ||
| Q2 25 | $-0.85 | $-0.31 | ||
| Q1 25 | $-0.65 | $-0.10 | ||
| Q4 24 | $-0.65 | $0.36 | ||
| Q3 24 | $-0.54 | $-0.98 | ||
| Q2 24 | $-0.58 | $-1.88 | ||
| Q1 24 | $-0.55 | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $255.7M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $246.0M | $4.6M |
| Total Assets | $301.1M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | $255.7M | — | ||
| Q1 25 | $318.2M | — | ||
| Q4 24 | $370.9M | $3.3M | ||
| Q3 24 | $253.8M | $1.3M | ||
| Q2 24 | $280.2M | $1.9M | ||
| Q1 24 | $299.3M | $2.4M |
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $246.0M | $3.0M | ||
| Q1 25 | $298.4M | $3.6M | ||
| Q4 24 | $336.5M | $3.5M | ||
| Q3 24 | $218.7M | $2.0M | ||
| Q2 24 | $228.3M | $3.6M | ||
| Q1 24 | $249.9M | $6.7M |
| Q4 25 | — | $6.1M | ||
| Q3 25 | — | $6.2M | ||
| Q2 25 | $301.1M | $5.5M | ||
| Q1 25 | $362.6M | $6.7M | ||
| Q4 24 | $418.5M | $7.2M | ||
| Q3 24 | $300.9M | $7.2M | ||
| Q2 24 | $324.2M | $9.8M | ||
| Q1 24 | $329.2M | $11.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-62.6M | $-1.1M |
| Free Cash FlowOCF − Capex | $-63.8M | — |
| FCF MarginFCF / Revenue | -1196.5% | — |
| Capex IntensityCapex / Revenue | 22.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-194.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-62.6M | $-2.0M | ||
| Q1 25 | $-53.1M | $-966.0K | ||
| Q4 24 | $-35.8M | $-687.0K | ||
| Q3 24 | $-39.0M | $-683.0K | ||
| Q2 24 | $-20.2M | $-659.0K | ||
| Q1 24 | $-31.2M | $-2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | $-63.8M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $-40.6M | — | ||
| Q2 24 | $-21.1M | — | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -48.9% | ||
| Q2 25 | -1196.5% | — | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | — | ||
| Q3 24 | -385.8% | — | ||
| Q2 24 | -222.4% | — | ||
| Q1 24 | -277.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 10.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EYPT
Segment breakdown not available.
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
